259 related articles for article (PubMed ID: 35273398)
1. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
[TBL] [Abstract][Full Text] [Related]
2. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
Xie BY; Wu AW
Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
[TBL] [Abstract][Full Text] [Related]
3. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids.
Mao Y; Wang W; Yang J; Zhou X; Lu Y; Gao J; Wang X; Wen L; Fu W; Tang F
Protein Cell; 2024 Apr; 15(4):285-304. PubMed ID: 37345888
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
[TBL] [Abstract][Full Text] [Related]
6. Prospective derivation of a living organoid biobank of colorectal cancer patients.
van de Wetering M; Francies HE; Francis JM; Bounova G; Iorio F; Pronk A; van Houdt W; van Gorp J; Taylor-Weiner A; Kester L; McLaren-Douglas A; Blokker J; Jaksani S; Bartfeld S; Volckman R; van Sluis P; Li VS; Seepo S; Sekhar Pedamallu C; Cibulskis K; Carter SL; McKenna A; Lawrence MS; Lichtenstein L; Stewart C; Koster J; Versteeg R; van Oudenaarden A; Saez-Rodriguez J; Vries RG; Getz G; Wessels L; Stratton MR; McDermott U; Meyerson M; Garnett MJ; Clevers H
Cell; 2015 May; 161(4):933-45. PubMed ID: 25957691
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
Ren X; Chen W; Yang Q; Li X; Xu L
J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
[TBL] [Abstract][Full Text] [Related]
8. Drug screening by uniform patient derived colorectal cancer hydro-organoids.
Jung YH; Choi DH; Park K; Lee SB; Kim J; Kim H; Jeong HW; Yang JH; Kim JA; Chung S; Min BS
Biomaterials; 2021 Sep; 276():121004. PubMed ID: 34273688
[TBL] [Abstract][Full Text] [Related]
9. Modeling colorectal cancers using multidimensional organoids.
Sayed IM; El-Hafeez AAA; Maity PP; Das S; Ghosh P
Adv Cancer Res; 2021; 151():345-383. PubMed ID: 34148617
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9-mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes.
Takeda H; Kataoka S; Nakayama M; Ali MAE; Oshima H; Yamamoto D; Park JW; Takegami Y; An T; Jenkins NA; Copeland NG; Oshima M
Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15635-15644. PubMed ID: 31300537
[TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P
ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669
[TBL] [Abstract][Full Text] [Related]
12. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
[TBL] [Abstract][Full Text] [Related]
13. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer.
Norkin M; Ordóñez-Morán P; Huelsken J
Cell Rep; 2021 Apr; 35(3):109026. PubMed ID: 33882314
[TBL] [Abstract][Full Text] [Related]
14. Modeling colorectal cancer: A bio-resource of 50 patient-derived organoid lines.
Engel RM; Jardé T; Oliva K; Kerr G; Chan WH; Hlavca S; Nickless D; Archer SK; Yap R; Ranchod P; Bell S; Niap A; Koulis C; Chong A; Wilkins S; Dale TC; Hollins AJ; McMurrick PJ; Abud HE
J Gastroenterol Hepatol; 2022 May; 37(5):898-907. PubMed ID: 35244298
[TBL] [Abstract][Full Text] [Related]
15. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
Sasaki N; Clevers H
Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
[TBL] [Abstract][Full Text] [Related]
16. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
Weeber F; van de Wetering M; Hoogstraat M; Dijkstra KK; Krijgsman O; Kuilman T; Gadellaa-van Hooijdonk CG; van der Velden DL; Peeper DS; Cuppen EP; Vries RG; Clevers H; Voest EE
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13308-11. PubMed ID: 26460009
[TBL] [Abstract][Full Text] [Related]
17. Organoid in colorectal cancer: progress and challenges.
Ji DB; Wu AW
Chin Med J (Engl); 2020 Aug; 133(16):1971-1977. PubMed ID: 32826461
[TBL] [Abstract][Full Text] [Related]
18. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer.
Cristobal A; van den Toorn HWP; van de Wetering M; Clevers H; Heck AJR; Mohammed S
Cell Rep; 2017 Jan; 18(1):263-274. PubMed ID: 28052255
[TBL] [Abstract][Full Text] [Related]
19. A growth factor-reduced culture system for colorectal cancer organoids.
Tan R; Zhang Z; Ding P; Liu Y; Liu H; Lu M; Chen YG
Cancer Lett; 2024 Apr; 588():216737. PubMed ID: 38382667
[TBL] [Abstract][Full Text] [Related]
20. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.
Lannagan TRM; Lee YK; Wang T; Roper J; Bettington ML; Fennell L; Vrbanac L; Jonavicius L; Somashekar R; Gieniec K; Yang M; Ng JQ; Suzuki N; Ichinose M; Wright JA; Kobayashi H; Putoczki TL; Hayakawa Y; Leedham SJ; Abud HE; Yilmaz ÖH; Marker J; Klebe S; Wirapati P; Mukherjee S; Tejpar S; Leggett BA; Whitehall VLJ; Worthley DL; Woods SL
Gut; 2019 Apr; 68(4):684-692. PubMed ID: 29666172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
